Pure Global
NCT05731089

IVI Aflibercept Before and After Phaco in DME.

Pre-Operative Versus Post-Operative Intravitreal Aflibercept Injection for Management of DME in Patients Undergoing Cataract Surgery
Al Hadi Hospital·ClinicalTrials.gov·procedureCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetic Macular Edema
Drug/Device/Intervention
Phacoemulsification with IVI of aflibercept
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Al Hadi Hospital
Location
Al Qādisīyah, Kuwait
Timeline & enrollment
Phase
N/A
Start date
Sep 01, 2019
End date
Dec 01, 2022
Enrollment
40 participants
Primary outcome

resolving of macular edema

Summary

To study whether or not cataract surgery should be deferred until treating the co-existing
 diabetic macular edema (DME) using intravitreal (IVI) anti-vascular endothelial growth factor
 (anti-VEGF).

ICD-10 classifications
Diabetic retinopathyOther specified diabetes mellitus with ophthalmic complicationsUnspecified diabetes mellitus with ophthalmic complicationsDiabetic cataractType 2 diabetes mellitus with ophthalmic complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05731089
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05731089 through Pure Global AI's free database. This phase not specified trial is sponsored by Al Hadi Hospital and is currently Completed. The study focuses on Diabetic Macular Edema. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.